Agoracom Blog Home

Archive for the ‘Predictmedix Inc.’ Category

Predictmedix’s Progress Paves the Way: Navigating Industry Success with Groundbreaking Health Innovations

Posted by Brittany McNabb at 10:06 AM on Friday, November 17th, 2023

In the fast-evolving landscape of health and safety, Predictmedix emerges as a beacon of innovation with its revolutionary Safe Entry Stations. As industries worldwide seek cutting-edge solutions, Predictmedix’s Safe Entry Stations are not only different; they are setting a new standard. This article delves into the unique features that set these stations apart and explores the notable companies embracing this transformative technology.

Revolutionizing Entry Protocols:

Predictmedix’s Safe Entry Stations go beyond traditional entry protocols. Unlike standard screening processes, these stations employ advanced artificial intelligence (AI) to conduct rapid, non-invasive health assessments. The technology ensures a swift yet comprehensive analysis, redefining how entry points are managed in various industries.

Differentiators that Matter:

What sets Predictmedix’s Safe Entry Stations apart are their multifaceted capabilities. From face detection and SOP violation detection to body temperature measurement, heart rate monitoring, and even assessing blood pressure, these stations offer a holistic health screening experience. The integration of these features positions Predictmedix as a leader in providing comprehensive health and safety solutions.

Companies Embracing the Future:

Notable industry leaders are recognizing the transformative potential of Predictmedix’s Safe Entry Stations. Companies across sectors, from healthcare to education, manufacturing, and more, are integrating these stations into their daily operations. This broad acceptance is a testament to the stations’ adaptability and effectiveness in diverse environments.

Healthcare Institutions Leading the Way:

In the healthcare sector, where precision and efficiency are paramount, Predictmedix’s Safe Entry Stations find prominent application. Hospitals, clinics, and medical facilities are leveraging this technology to ensure the safety of both staff and patients. The stations’ accuracy in detecting vital signs, including potential COVID-19 symptoms, positions them as a crucial asset in the ongoing battle against the pandemic.

Ensuring Safe Learning Environments:

Predictmedix’s Safe Entry Stations are making waves in the education sector. Schools, colleges, and vocational training institutes are embracing this technology to create safe learning environments. The stations not only enhance safety but also provide a real-world application of AI, offering an educational experience beyond textbooks.

Manufacturing and Corporate Spaces:

Beyond healthcare and education, manufacturing and corporate sectors are integrating Predictmedix’s Safe Entry Stations into their facilities. These stations contribute to creating secure workplaces by identifying potential health risks among employees, ensuring a proactive approach to employee well-being and safety.

Revolutionizing Health Screening with 95% Accuracy:

The recent clinical validation breakthrough, achieving a remarkable 95% accuracy, is a testament to Predictmedix’s dedication to excellence. This milestone propels the company to the forefront of health screening, introducing a level of precision that redefines the standards in the industry.

Showcasing Revolutionary Health and Safety Solutions:

Predictmedix doesn’t merely embrace industry trends; it showcases revolutionary solutions. At the D-30 event in New Delhi, the company presented groundbreaking health and safety solutions, emphasizing its commitment to fostering a global culture of well-being and safety.

Revolutionizing the Global Fight Against Drug Addiction:

Predictmedix’s cutting-edge screening technology emerges as a game-changer in the fight against drug addiction. Beyond identification, the technology’s utility extends to managing patient health, providing a comprehensive solution for a safer, drug-free world.

Real-world Impact:

The real-world impact of Predictmedix’s Safe Entry Stations is tangible. Beyond the buzz of innovation, these stations are actively reshaping how companies manage health and safety, ensuring compliance with protocols, and fostering a culture of well-being.

Conclusion:

In conclusion, Predictmedix’s Safe Entry Stations represent a paradigm shift in health and safety solutions. Their widespread adoption across diverse industries underscores their versatility and effectiveness. As companies worldwide seek to redefine their approach to health screening, Predictmedix stands at the forefront, offering a transformative solution that goes beyond compliance—it pioneers a new era in health and safety. Investors keen on companies leading the charge in innovative health technologies should keep a close eye on Predictmedix and its pioneering Safe Entry Stations.

 

YOUR NEXT STEPS

Visit $PMED HUB On AGORACOM: https://agoracom.com/ir/Predictmedixhttps 

Visit $PMED 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Predictmedix/profile

Visit $PMED Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Predictmedix/forums/discussion

Watch $PMED Videos On AGORACOM YouTube Channel:

https://www.youtube.com/feed/library

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit  https://agoracom.com/terms-and-conditions

Predictmedix AI Revolutionizes Health Screening with 95% Accuracy: A Breakthrough Clinical Validation

Posted by Brittany McNabb at 7:54 AM on Tuesday, November 14th, 2023

In a groundbreaking move toward advancing health screening technology, Predictmedix AI Inc. has achieved a significant milestone with a successful clinical validation at the University of Raharja, Indonesia. This accomplishment, marked by a remarkable 95% accuracy in vital sign detection, underscores Predictmedix’s commitment to prioritizing well-being through cutting-edge artificial intelligence (AI).

Predictmedix AI, a leader in rapid health screening solutions, has a rich history of leveraging AI to redefine safety culture and enhance the physical and mental well-being of individuals. This collaborative effort with the University of Raharja is a testament to the company’s dedication to innovation and its mission to foster a “Fit for Duty” culture.

Key Highlights and Advantages:

The clinical study aimed to develop non-invasive AI-based software capturing vital signs, including heart rate, respiration rate, height, body temperature, and blood pressure.

Notably, the solution prioritizes privacy by avoiding recognizable facial images while ensuring accurate and consistent vital sign readings.

Key features include face detection, SOP violation detection, body temperature detection, heart rate monitoring, respiration rate monitoring, SpO2 measurement, height assessment, and blood pressure measurement.

Potential Impact and Significance:

The clinical validation, with an impressive 95% accuracy across critical parameters, is a monumental achievement. Predictmedix AI’s solution holds the potential to revolutionize health screening, creating safer and more efficient workplaces globally. The iterative refinements in the AI algorithms ensure continuous improvement, with an accuracy range between 90% and 99% for all vital signs.

Expert Opinions and Analysis:

Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI, expressed the significance of this milestone, stating, “The accuracy and maturity of our AI solution, especially in vital sign screening, are truly rewarding. We eagerly anticipate exploring broader applications to benefit society.” Raharja University endorses Predictmedix’s Safe Entry Station solution, highlighting its effectiveness in non-invasive patient screening for various conditions.

Challenges and Considerations:

While the clinical validation marks a substantial achievement, potential challenges in adoption and implementation may arise. Predictmedix AI is well-prepared to address these challenges, ensuring the continuous refinement and reliability of their AI solution.

Predictmedix AI’s breakthrough in achieving 95% accuracy in vital sign detection heralds a new era in health screening technology. This accomplishment reinforces the company’s position as a leader in the field and sets the stage for broader applications that can benefit society at large. As Predictmedix continues to innovate, its commitment to fostering a safer and healthier global community remains unwavering.

View original release: https://predictmedix.com/predictmedix-ai-announces-successful-clinical-validation-at-the-university-of-raharja-indonesia-demonstrating-95-accuracy-in-vital-sign-detection/ 

 

Predictmedix AI Showcases Revolutionary Health and Safety Solution at D-30 Event in New Delhi

Posted by Brittany McNabb at 10:37 AM on Monday, November 6th, 2023

Predictmedix AI Inc., a leading force in rapid health screening solutions driven by artificial intelligence (AI), marked a monumental moment at the D-30 event in New Delhi, India. This international summit, uniting 30 nations under the United Nations banner, signifies a pivotal step forward in the collective global fight against drug addiction and the ensuing disabilities it causes.

Predictmedix AI is at the forefront of leveraging AI technology to revolutionize health screening and remote patient care solutions worldwide. Their Safe Entry Stations, powered by proprietary AI, employ multispectral cameras to analyze physiological data patterns, predict vital parameters, and detect impairment, fatigue, or various mental health conditions.

Key Highlights and Advantages:

The introduction of Predictmedix AI’s Safe Entry Stations at the D-30 event unveiled a groundbreaking solution that has far-reaching implications for diverse environments. These stations provide rapid, non-invasive health assessments, including impairment detection, creating safer workplaces and communities.

Potential Impact and Significance:

The event in New Delhi served as a powerful platform for sharing knowledge and innovative solutions to combat drug addiction. Predictmedix AI’s participation and the introduction of Safe Entry Stations underscore their commitment to global well-being and their pivotal role in the fight against drug addiction and its associated disabilities.

Expert Opinions and Analysis:

Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI, emphasized the company’s mission to address pressing global health and safety concerns. He expressed honor in showcasing their Safe Entry Stations to representatives from 30 nations committed to promoting a safer world. Furthermore, the positive impact of this technology in education and skill development at a prominent institute in India opens another vertical for its application.

While the technology holds great promise, potential challenges in adoption and implementation may arise. Predictmedix AI is well-prepared to navigate these hurdles through strategic partnerships and ongoing innovation.

Predictmedix AI’s participation in the D-30 event is a testament to their pivotal role in combating drug addiction globally. The Safe Entry Stations represent a beacon of hope, providing a path towards a safer, drug-free world. With visionary leaders like Colonel G. Srikumar (Retd) at the helm, the company is poised to accelerate its impact not only in India but also in international markets, marking a significant milestone in Predictmedix AI’s journey towards global leadership in advanced AI technologies.

View Original Release: https://predictmedix.com/predictmedix-ai-unveils-safe-entry-stations-to-delegates-from-30-nations-at-d-30-event-in-new-delhi/

Predictmedix AI Embarks on Pioneering International Expansion, Ushering in New Era of AI Solutions

Posted by Brittany McNabb at 8:51 AM on Friday, October 27th, 2023

Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) has returned from an extensive international campaign, marking a pivotal moment in the company’s journey toward global leadership in advanced AI technologies. The month-long endeavor witnessed the attainment of significant milestones across various domains of corporate development.

Strategic alliances forged during this period are set to reshape industries, particularly within the healthcare sector, as Predictmedix AI pioneers new applications for AI-driven solutions. Concurrently, the company has solidified collaborations with key government organizations, aligning with regulatory initiatives and fostering innovation.

Focusing on healthcare transformation, Predictmedix AI deepened its engagement within the sector, showcasing its unwavering commitment to redefining patient care and diagnosis through cutting-edge AI technologies. Moreover, the company’s expansion has not been confined to healthcare alone. By exploring opportunities in non-healthcare verticals, Predictmedix AI has expanded its influence and harnessed its AI expertise to contribute to a broader spectrum of industries.

This dynamic phase also witnessed a strategic augmentation of the company’s talent pool, with key individuals joining the team, poised to accelerate business development efforts. Dr. Rahul Kushwah, COO of Predictmedix AI, conveyed his excitement about the campaign’s outcomes, noting that the initiative provided an invaluable platform to reiterate the company’s commitment to innovation and regulatory compliance.

Furthermore, Predictmedix AI is actively pursuing Bureau of Indian Standards (BIS) and Central Drugs Standard Control Organization (CDSCO) certifications to uphold the quality and compliance of its healthcare solutions, in response to burgeoning client demands for commercial orders.

In a simultaneous move, the company has established a corporate address in San Francisco, USA, further solidifying its global presence.

The company’s agreements with two distinguished consultants, integral to the development of its technologies, further underpin its dedication to innovation. In acknowledgment of their contributions, Predictmedix AI will issue a total of 2,000,000 common shares, cementing its commitment to collaborative progress in the field of advanced AI solutions.

View original release: https://predictmedix.com/predictmedix-ai-accelerates-corporate-expansion-during-month-long-international-campaign/

Predictmedix AI’s 2023 Breakthroughs: Revolutionizing Healthcare with AI

Posted by Brittany McNabb at 1:02 PM on Thursday, September 7th, 2023

Predictmedix AI Inc. (CSE: PMED, OTCQB: PMEDF), a pioneering leader in AI-driven healthcare solutions, has made significant strides in 2023, reaffirming its position at the forefront of the healthcare technology revolution. With a focus on innovation, technology validation, and strategic partnerships, Predictmedix AI is poised to transform patient care and safety on a global scale. In this article, we’ll delve into the company’s achievements and advancements this year.

Technological Advancements

Predictmedix AI has achieved remarkable technological advancements in 2023:

  • Comprehensive Triage Solution: The company’s Triage Solution now encompasses 16 vital parameters, including temperature, heart rate, BMI, and blood pressure, enhancing its accuracy and versatility in the healthcare landscape.
  • Unprecedented Dataset: Over 200,000 individuals have been scanned using AI-powered Safe Entry Stations, creating an unparalleled dataset for accurate analysis. This milestone significantly improves machine learning accuracy across healthcare and other industries.
  • Cardiovascular Parameters Measurement: Predictmedix introduces groundbreaking technology to measure heart rate variability, respiration rate, and blood pressure non-invasively, providing valuable insights into patients’ cardiovascular health.
  • Diabetes Screening Innovation: The company has innovated diabetes screening without the need for biological fluids, expanding diagnostic reach, particularly in regions like India where diabetes is a significant health concern.
  • Revolutionary Fitness Scan: Predictmedix has introduced a first-to-market fitness scan vertical that utilizes advanced machine learning algorithms. This innovation empowers athletes to optimize their training and performance.
  • US Patent for Impairment Screening: Predictmedix has been granted a US patent for its AI-powered impairment detection technology, designed for alcohol and cannabis screening.

Technology Validation

Predictmedix AI’s technology has undergone rigorous validation:

  • Independent Clinical Validation: The company’s technology has been independently validated in hospitals and universities in India and Indonesia, establishing its credibility in real-world healthcare settings.
  • International Recognition: Leading newspapers in India and Indonesia have featured Predictmedix’s technology for its cost-saving and efficiency-improving capabilities in healthcare.

Value Proposition with Safe Entry Stations

Predictmedix’s Safe Entry Stations offer substantial benefits to the healthcare industry:

  • Labor Cost Reduction: Automating screenings reduces manual effort, allowing healthcare staff to focus on critical tasks.
  • Efficient Patient Flow: Faster screenings lead to reduced wait times and increased patient throughput, enhancing overall efficiency.
  • Preventive Measures: Early identification of potential risks helps prevent contagious outbreaks and improve public health.
  • Resource Allocation Optimization: Accurate identification of symptomatic individuals enables better allocation of healthcare resources.
  • Legal and Liability Mitigation: Early detection minimizes legal liabilities and reputational damage for healthcare providers.
  • Improved Infection Control: Preventing symptomatic individuals from entering healthcare facilities enhances infection control and patient outcomes.

Commercialization and Business Development

Predictmedix AI’s strategic commercialization efforts and business development activities in 2023 include:

  • Indonesia and ASEAN Market: The company is tapping into the vast healthcare market potential in Indonesia and the ASEAN region. Collaborations with prestigious institutions for tailored research and development are underway.
  • Indian Healthcare Opportunity: Predictmedix is capitalizing on India’s growing healthcare needs, forging collaborations with government officials and departments to address critical healthcare challenges.
  • Indian Subsidiary: “Predictmedix India Pvt Ltd” has been established to expedite collaborations and development in India, showcasing the company’s commitment to the Indian healthcare sector.
  • Strategic Supplier Partnership: Engaging with an Indian supplier for mass production of Safe Entry Stations enhances production capacity and accessibility, facilitating the deployment of this technology.

As Predictmedix AI continues its journey to redefine healthcare through innovation, technology validation, and strategic global expansion, the company remains steadfast in its vision of creating a safer, more efficient, and accessible healthcare landscape for all.

With a strong foundation of achievements in 2023, including expanded solutions, international recognition, and strategic partnerships, Predictmedix AI is poised to lead the charge in AI-driven healthcare solutions

 

YOUR NEXT STEPS

Visit $PMED HUB On AGORACOM: https://agoracom.com/ir/Predictmedix

Visit $PMED 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Predictmedix/profile

Visit $PMED Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Predictmedix/forums/discussion

Watch $PMED Videos On AGORACOM YouTube Channel:

https://www.youtube.com/channel/UCxiA6FAQm7rPqb2Gl9pJ1-Q

 

DISCLAIMER AND DISCLOSURE 

 This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. 

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

 From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit  https://agoracom.com/terms-and-conditions

Predictmedix $PMED.ca $PMEDF Announces Technology Deployments at Major Office Towers in Calgary and Edmonton in Partnership With Aspen Properties $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 9:51 AM on Monday, April 19th, 2021
PMED PredictMedix

TORONTO, April 19, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce deployment of Safe Entry Stations at 4 key office towers in downtown Calgary and Edmonton in partnership with Apsen Properties and Juiceworks Exhibits (Juiceworks).

Calgary’s The Edison, Palliser Complex, The Ampersand and Edmonton’s Bell Tower are raising the bar by providing a completely voluntary infectious disease symptom screening option for their tenants. This is a multi-unit, 24 month contract.

Safe Entry Stations are powered by artificial intelligence (AI).  Military-grade multispectral cameras use thermal imaging and a proprietary hardware configuration to capture data patterns that are analyzed instantly.

They provide an immediate assessment of individuals looking to access shared spaces by screening for multiple symptoms associated with infectious diseases, such as COVID-19. Moreover, the technology is 100% non-invasive, expediting the screening process even at high volume locations.

This ground-breaking technology is poised to change the way we look at the screening and diagnosis of infectious diseases. Our autonomous, comprehensive AI algorithms are continuously evolving via machine learning, are deployed instantly on the cloud, and deliver a multi-symptom analysis within seconds.

Read More: https://agoracom.com/ir/Predictmedix/forums/discussion/topics/759282-predictmedix-announces-technology-deployments-at-major-office-towers-in-calgary-and-edmonton-in-partnership-with-aspen-properties/messages/2312537#message

Predictmedix $PMED.ca $PMEDF Announces a 2-Year Revenue Contract With Flow Alkaline Spring Water for North American Operations $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 10:49 AM on Wednesday, April 14th, 2021
PMED PredictMedix

TORONTO, April 14, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce a 24 month, multi-unit contract to deploy Safe Entry Stations throughout the North American operations of Flow Water Inc. (“Flow Alkaline Spring Water” or “Flow”). The partnership marks the successful completion of our initial pilot, as the technology is now scaled and deployed across all of Flow’s operations both in Canada and the USA.

A pioneer in the health and wellness arena, Flow was one of the first in Eastern Canada to partner with Predictmedix and Juiceworks Exhibits (JUICEWORKS) to implement Safe Entry Stations at their Aurora facilities in August 2020. North America’s first socially responsible artisan alkaline water plant, Flow continues its spirit of innovation by incorporating AI-powered solutions to improve operational efficiencies.

Initially deployed as a beta site, Safe Entry quickly became an integral part of Flow’s health and safety protocol. The autonomous nature of the technology and the robust multi-symptom screening imparted an added sense of security among their workforce.

As part of their ongoing commitment to their valued staff, they have entered into a multi-unit revenue contract for two years and will now be expanding the program to their remaining facilities in Aurora, Ontario and Verona, Virginia.

“Implementing Safe Entry at our plants has dramatically decreased our absenteeism and increased employee peace of mind. Keeping our staff safe is top priority, and as such, we were determined to implement the best available solution, which we found in Safe Entry,” affirms Nicholas Reichenbach, Founder & Executive Chairman of Flow.

Read More: https://agoracom.com/ir/Predictmedix/forums/discussion/topics/759031-predictmedix-announces-a-2-year-revenue-contract-with-flow-alkaline-spring-water-for-north-american-operations/messages/2311881#message

VIDEO – Predictmedix $PMED.ca $PMEDF Preps for Big Year Ahead, as Demand for its Contactless Screening Devices sees Ramp Up of Partnerships, M&A and Strategic Financing $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM-JC at 2:44 PM on Tuesday, April 13th, 2021
Predictmedix Inc. (CSE: PMED | OTCQB: PMEDF) | LinkedIn

Predictmedix is an Artificial Intelligence company that has developed fast, non-invasive, contactless screening devices that detect infectious diseases, impairment and even mental illness at any location where mass amounts of people gather, such as:

  • Hospitals
  • Stadiums
  • Airports
  • Malls
  • Government Buildings
  • Office Complexes

These screeners are fully automated and intelligent, so they don’t need personnel to operate them. They determine the probability of a person being infected with illnesses such as COVID-19, so safety protocols can be initiated.

Earlier this month, the AI firm penned a major strategic partnership with Juiceworks and Connectus Global to deploy its Safe Entry Stations nationwide.

That news came during an increasingly busy time for $PMED, which has included:

  • An LOI to acquire AI-powered tech firm Symp2Pass
  • The engagement of investment banking firm Kingswood Capital Markets in preparation for NASDAQ listing
  • Major partnerships
  • Strategic financing developments


You’re going to want to get comfy for this chat with Predictmedix COO & Director Rahul Kushwah:

Predictmedix $PMED.ca $PMEDF and JUICEWORKS Form Strategic Partnership with CONNECTUS Global to Deploy Safe Entry Stations Nationwide $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 9:09 AM on Monday, April 5th, 2021
PMED PredictMedix

TORONTO, April 05, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”) is pleased to announce a partnership to deploy Safe Entry Stations in partnership with North American industry leaders JUICEWORKS EXHIBITS (JUICEWORKS) and CONNECTUS Global.

SAFE ENTRY STATIONS leverage military-grade multispectral cameras paired with Predictmedix’s proprietary, clinically based artificial intelligence algorithms. They provide an immediate assessment of individuals looking to access shared spaces by checking for multiple symptoms associated with infectious diseases such as COVID-19.

This ground-breaking technology is poised to change the way we look at screening and, eventually, the diagnosis of infectious diseases. Autonomous, comprehensive analysis provides peace of mind to individuals entering shared spaces, be it for work, entertainment, or necessity.

Mike Anderson, CEO of CONNECTUS Global, commented:

“Seeing this level of innovation is exciting to drive adoption of digital processes throughout the public and private sectors, what PREDICTMEDIX and JUICEWORKS are doing is revolutionary to introduce a new level of health measurement into the community.”

Read More: https://agoracom.com/ir/Predictmedix/forums/discussion/topics/758511-predictmedix-and-juiceworks-form-strategic-partnership-with-connectus-global-to-deploy-safe-entry-stations-nationwide/messages/2310850#message

Predictmedix Inc. $PMED.ca $PMEDF Announces Engagement of Investment Banking Firm Kingswood Capital Markets $PFM.ca $VQS.ca $SPOT.ca $ADK.ca

Posted by AGORACOM at 10:14 AM on Monday, March 29th, 2021
PMED PredictMedix

TORONTO, March 29, 2021 (GLOBE NEWSWIRE) — Predictmedix Inc. (CSE:PMED) (OTCQB:PMEDF) (“Predictmedix” or the “Company”), a leader in providing AI-powered healthcare solutions is pleased to announce that it has appointed Kingswood Capital Markets (“Kingswood”) in preparation to become a NASDAQ-listed company.

The acceptance of the application to list the Company’s common shares on NASDAQ will be subject to a number of regulatory and listing requirements, including without limitation: retaining the required number of market makers for the Company’s common shares; the filing of the applicable registration statement with the U.S. Securities and Exchange Commission to become a reporting company under the U.S. Securities Act; and the review of the Company and acceptance for listing by NASDAQ. There can be no assurance that NASDAQ acceptance will be granted should the Company submit its listing application.

Kingswood Capital Markets is a global full-service middle market investment bank. Kingswood helps its clients grow through optimal capital raising structures. Its team of experienced investment professionals has collectively financed over $50 billion in public and private capital markets and provides strategic solutions to clients across a wide spectrum of industries.

Kingswood’s expertise has been engaged to aid in both Predictmedix’s NASDAQ uplist and business growth, as part of the Company’s endeavors to disrupt the current healthcare and technology market in a safe, non-invasive, and economically sustainable way.

Read More: https://agoracom.com/ir/Predictmedix/forums/discussion/topics/758166-predictmedix-inc-announces-engagement-of-investment-banking-firm-kingswood-capital-markets/messages/2310138#message